The Effect of Hesperidin on Glucose / Insulin Metabolism

The Effect of Hesperidin Administration on Glucose / Insulin Metabolism

Metabolic Syndrome (MS) is a well-known group of obesity-related metabolic disorders including insulin resistance (IR), dyslipidemia and hypertension (HTN). In addition, overweight has a causal relationship with a chronic low grade systemic inflammatory condition and increased intestinal permeability. Over the last decade, this multiplex disorder has progressively become a major worldwide public health problem, because of its association with increased risk of type 2 diabetes mellitus (DM2), atherosclerotic cardiovascular disease and all-cause mortality. Scientific evidence for measures to improve cardiometabolic and intestinal health by non-pharmaceutical means are of urgent need. Administration of the flavonoid hesperidin to those at risk may have beneficial effects on glucose / insulin metabolism, lipid metabolism, blood pressure, heart rate, pro-inflammatory and oxidative stress biomarkers and gut barrier function.

Objective: To determine the 12-week effect of daily administration of hesperidin on the main cardiometabolic disorders related to MS as assessed by investigation of glucose/insulin metabolism, blood lipid profile, blood pressure, heart rate, body composition and gut barrier function in subjects at risk for MS.

Study design: This is a randomized, double-blind, placebo-controlled study with parallel design.

Study population: Healthy (male/female) volunteers, age 18-65, at risk for metabolic syndrome (presenting with 2 out of 5 of the components from NCEP-ATP-III criteria).

Intervention: Participants will be randomly assigned to one of the intervention groups. One group will receive one daily dose of hesperidin capsules while the other group receives identical looking placebo capsules for a period of 12 weeks. The capsules will have to be ingested with a glass of water every morning just before breakfast.

Main study parameters/endpoints: The primary efficacy parameter of this study is the oral glucose tolerance test (OGTT), a validated surrogate endpoint to study the β-cell function and insulin sensitivity. Secondary endpoints entail the evaluation of effects of daily administration of hesperidin on lipid profile (blood measurements), blood pressure and heart rate, body composition, low-grade inflammation biomarkers (blood measurements) and gut barrier function (blood measurements, fecal samples, urine collection).

Study Overview

• Status: Completed
• Conditions: Obesity; Metabolic Syndrome
• Intervention / Treatment: Dietary supplement: Placebo; Dietary supplement: Hesperidin

• Study Type: Interventional
• Enrollment (Actual): 53
• Phase: Phase 2

Contacts and Locations

Study Locations

• Netherlands
  • Limburg
    • Maastricht, Limburg, Netherlands, 6221EG
      • MUMC+

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

* Subjects at risk for metabolic syndrome: a combination of 2 out of 5 components:

• Waist circumference: men > 102 cm / women > 88 cm
• Triglycerides: ≥ 1.7 mmol/l
• HDL-cholesterol: men ≤ 1.0 mmol/l / women ≤ 1.3 mmol/l
• Systolic blood pressure: ≥ 130 mmHg or diastolic blood pressure: ≥ 85 mmHg
• Fasted serum glucose ≥ 6.1 mmol/L

Exclusion Criteria:

• Type 2 diabetes mellitus (defined as fasting plasma glucose ≥7.0 mmol/l)
• Gastroenterological diseases or abdominal surgery
• Cardiovascular diseases, cancer, liver or kidney malfunction, thyroid disorders, disease with a life expectancy shorter than 5 years
• Self-admitted HIV-positive status
• Abuse of products; alcohol (> 20 alcoholic consumptions per week) and drugs
• Smoking
• Plans to lose weight or following a hypocaloric diet during the study period
• Weight gain or loss > 3 kg in previous 3 months
• Use of medication interfering with endpoints
• Use of antioxidants, minerals and vitamin supplements available in pharmacies, drugstores, food markets or in alternative medicine
• Hormone replacement therapy (women).
• Use of antibiotics in the 90 days prior to the start of study
• Administration of investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principle investigator) in the 180 days prior to the study
• Known pregnancy (assessed by a pregnancy test before start of study) or lactation
• Blood donation within 3 months before study period
• Failure to comply prohibited intake of hesperidin containing food products during study period. A list with forbidden products will be provided to participants
• History of any side effects towards the intake of flavonoids or citrus fruits

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; Cellulose	Dietary supplement: Placebo; Cellulose
Active Comparator: Hesperidin; Citrus peel extract	Dietary supplement: Hesperidin; Citrus peel extract

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Effect on blood glucose concentrations measured by oral glucose tolerance test	12 weeks

Secondary Outcome Measures

Outcome Measure	Time Frame
Effect on blood lipid profile	12 weeks
Effect on blood pressure	12 weeks
Effect on body composition measured by BMI	12 weeks
Effect on low-grade inflammation measured by blood concentration of TNFalfa	12 weeks
Effect on low-grade inflammation measured by blood concentration of interleukin-6	12 weeks
Effect on gut barrier function measured by a sugar test	12 weeks

Collaborators and Investigators

• Sponsor: Maastricht University Medical Center
• Investigators: Principal Investigator: Ad Masclee, MD, Maastricht University Medical Center

Study record dates

Study Major Dates

• Study Start: February 1, 2015
• Primary Completion (Actual): October 1, 2015
• Study Completion (Actual): October 1, 2015

Study Registration Dates

• First Submitted: November 16, 2015
• First Submitted That Met QC Criteria: November 19, 2015
• First Posted (Estimate): November 20, 2015

Study Record Updates

• Last Update Posted (Estimate): November 20, 2015
• Last Update Submitted That Met QC Criteria: November 19, 2015
• Last Verified: November 1, 2015

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Insulin Resistance; Hyperinsulinism; Metabolic Syndrome
• Other Study ID Numbers: 143036